8158 — China Regenerative Medicine International Income Statement
0.000.00%
Last trade - 00:00
- HK$33.47m
- HK$82.50m
- HK$69.49m
R2019 December 31st | R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 19.4 | 182 | 283 | 232 | 69.5 |
Cost of Revenue | |||||
Gross Profit | 4.6 | 41.8 | 67.7 | 37.6 | 19.4 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 335 | 209 | 259 | 223 | 176 |
Operating Profit | -316 | -26.5 | 23.7 | 9.05 | -107 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -322 | -142 | 64.3 | 8.27 | -108 |
Provision for Income Taxes | |||||
Net Income After Taxes | -317 | -154 | 51.8 | 4.55 | -108 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -395 | -404 | 13.3 | 4.55 | -108 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -395 | -404 | 13.3 | 4.55 | -108 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.46 | -0.764 | 0.168 | 0.014 | -0.376 |